Nanobiotix S.A. – Sponsored ADR (NBTX) – What Are Researchers Thinking About This Stock?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $46.67.

Several analysts have commented on NBTX shares. Guggenheim initiated coverage on Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th.

Nanobiotix Trading Up 4.5%

Nanobiotix stock opened at $22.23 on Friday. The stock has a fifty day moving average price of $35.01 and a 200 day moving average price of $36.72. Nanobiotix has a 52 week low of $14.78 and a 52 week high of $57.14.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.

Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.

The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors.